ArticleRheumatology international2026
Nailfold videocapillaroscopy-defined capillaroscopic abnormality burden in systemic lupus erythematosus: a controlled cross-sectional study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesNailfold videocapillaroscopy (NVC) abnormalities are recognized in systemic lupus erythematosus (SLE), but their meaning remains uncertain. We examined whether standardized NVC quantifies structural capillaroscopic abnormality burden in SLE.
methodsIn this single-centre cross-sectional study, 65 SLE patients and 46 non-autoimmune controls underwent standardized NVC. Six parameters were semi-quantitatively scored and combined into microangiopathy, morphological, and total scores. Between-group associations were assessed using adjusted negative binomial regression. Within-SLE correlation, treatment-adjusted, and exploratory cluster analyses were performed.
resultsTotal score was higher in SLE than controls (15 [10-21] vs. 2 [0-4], p < 0.001). After adjustment for age, sex, BMI, smoking, diabetes, and hypertension, SLE was associated with total (IRR 7.64, 95% CI 4.93-11.84), microangiopathy (IRR 9.48, 95% CI 5.94-15.14), and morphological scores (IRR 5.99, 95% CI 3.84-9.35; all p < 0.001). Density loss showed the largest component-level estimate (IRR 129.68, 95% CI 30.67-548.26) and was interpreted cautiously because of sparse controls. Microhaemorrhages were not associated with SLE (IRR 1.35, p = 0.452). Within SLE, only giant capillaries showed nominal correlations with disease duration (ρ = 0.298, p = 0.016) and neutrophils (ρ = 0.271, p = 0.029); serological signals were FDR-negative. Organ-level models were largely negative; musculoskeletal and discoid signals attenuated after treatment adjustment. Exploratory clustering identified low/high-burden groups (n = 52/13; silhouette 0.479), with limited high-burden stability.
conclusionsStandardized NVC identified greater structural capillaroscopic abnormality burden in SLE, but not a surrogate for activity, serology, organ involvement, or treatment response. Prognostic or clinical utility requires prospective multicentre validation incorporating cumulative treatment exposure.
Indexed as
Identifiers
42701975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.